Ziltivekimab lowers inflammation but fails Phase 3 cardiovascular outcomes test
Ziltivekimab lowered IL-6 activity and hsCRP but failed to reduce major cardiovascular events in Novo Nordisk’s 6,300-patient ZEUS trial.
Pharma & Biotech